Welcome to our dedicated page for SAB BIOTHERAPEUTICS SEC filings (Ticker: SABS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SAB Biotherapeutics, Inc. (SAB BIO) SEC filings page for ticker SABS provides access to the company’s official regulatory disclosures as a clinical-stage biopharmaceutical issuer on Nasdaq. These documents are a primary source for detailed information on SAB BIO’s governance, equity structure, and other material corporate events related to its development of fully human immunoglobulin G (hIgG) and human anti-thymocyte immunoglobulin (hATG) therapies, including its lead program SAB-142 for autoimmune type 1 diabetes.
In SAB BIO’s Form 8-K filings, investors can find reports on matters such as Board of Directors changes and stockholder approvals. For example, one 8-K describes the resignation of two directors and a reduction in the size of the Board, noting that the departures were not due to disagreements over company operations, policies, or practices. Another 8-K details the results of a special meeting of stockholders, where stockholders approved amendments to the 2021 Omnibus Equity Incentive Plan, including increases in the maximum number of shares available under the plan and adjustments to the plan’s evergreen share increase, as well as approval of a proposal related to potential issuance of common stock upon conversion of Series B Convertible Preferred Stock under Nasdaq rules.
On Stock Titan, these and other SAB BIO filings are updated from the SEC’s EDGAR system and can be reviewed alongside AI-powered summaries. AI analysis helps explain complex items such as equity plan amendments, preferred stock conversion terms, and governance changes in clear language, saving time when reading lengthy forms. Users can quickly identify key sections of 8-Ks, 10-Ks, and 10-Qs, and can also monitor how equity incentives and capital structure decisions may relate to the company’s ongoing clinical development of SAB-142 and its broader human IgG platform.
For those researching SABS, this page centralizes SAB Biotherapeutics’ historical and current SEC reports, with tools to interpret the implications of each filing without manually parsing every line of legal and accounting text.
SAB Biotherapeutics, Inc. is the subject of a Schedule 13G showing that Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd., and Joseph Edelman collectively report beneficial ownership of 3,471,861 shares of SAB’s common stock, representing 7.3% of the class.
The Master Fund directly holds the 3,471,861 shares, and the ownership percentage is based on 47,606,851 outstanding shares as of November 10, 2025, as disclosed in SAB’s Form 10-Q. Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, share voting and dispositive power over these shares. The filers certify the position was not acquired to change or influence control of SAB Biotherapeutics.
SAB Biotherapeutics, Inc. reported that on January 12, 2026 it posted an updated corporate presentation on its official website. The presentation, dated January 12, 2026 and referenced as Exhibit 99.1, is intended for investors and other stakeholders seeking an overview of the company and its plans. The disclosure notes that this presentation is being furnished rather than filed under securities laws, meaning it is not automatically incorporated into other regulatory documents unless specifically referenced.
SAB Biotherapeutics, Inc. granted director Rita Jain a new equity award. On January 5, 2026, she received a stock option to purchase 240,000 shares of common stock at an exercise price of $3.74 per share. This represents her inaugural grant as a member of the company’s Board of Directors.
The option expires on January 5, 2036 and the underlying shares vest in three equal annual installments on January 5, 2027, January 5, 2028, and January 5, 2029. The award was made under SAB Biotherapeutics’ 2021 Omnibus Equity Incentive Plan, as amended, and is held directly by Jain.
SAB Biotherapeutics director David Zaccardelli received a new stock option grant. On January 5, 2026, he was awarded options to purchase 240,000 shares of SAB Biotherapeutics, Inc. common stock at an exercise price of $3.74 per share. The options expire on January 5, 2036 and were granted as his inaugural award for serving on the company’s Board of Directors.
The shares underlying this option vest in three equal annual installments on January 5, 2027, January 5, 2028, and January 5, 2029, and were issued under the company’s 2021 Omnibus Equity Incentive Plan, as amended. After this grant, he beneficially owns 240,000 derivative securities in the form of these options, held directly.
SAB Biotherapeutics, Inc. director Rita Jain filed an initial insider ownership report on Form 3 for the company’s common stock. As of the event date of 01/05/2026, the filing states that no securities of SAB Biotherapeutics are beneficially owned, and both the non-derivative and derivative securities tables show no holdings. This indicates that, while serving as a director, Jain reports no direct or indirect ownership in the company’s securities at the time of this filing.
SAB Biotherapeutics, Inc. director David Zaccardelli filed an initial beneficial ownership report on Form 3, with an event date of 01/05/2026. The filing states that no securities of SAB Biotherapeutics are beneficially owned, and both the non-derivative and derivative tables show no holdings.
SAB Biotherapeutics, Inc. reported that its board appointed David Zaccardelli, Pharm.D., and Rita Jain, M.D., as Class II directors effective January 5, 2026. They will serve until the 2026 annual meeting of stockholders or until successors are elected and qualified.
Dr. Zaccardelli has been named Chairperson of the Board, while Chief Executive Officer Samuel J. Reich steps down as chair but continues as a director. Both new directors were recommended by RA Capital Healthcare Fund, L.P. under a July 21, 2025 letter agreement related to a July 2025 private placement. They will receive compensation similar to other non-employee directors and have entered into customary indemnity agreements. On January 7, 2026, the company issued a press release announcing these appointments.
SAB Biotherapeutics, Inc. director Jay S. Skyler reported receiving a stock option grant as part of his 2025 annual compensation for serving on the board. On 12/16/2025, he was granted an option to purchase 150,000 shares of common stock at an exercise price of $3.99 per share.
The option was issued under the company’s 2021 Omnibus Equity Incentive Plan, as amended. The shares underlying this option vest in two equal annual installments on December 16, 2026 and December 16, 2027, meaning the director earns the right to exercise half the options on each of those dates if service conditions are met.
SAB Biotherapeutics, Inc. reported an equity award to director William James Polvino. On December 16, 2025, he received a stock option covering 150,000 shares of common stock at an exercise price of $3.99 per share. This grant represents his 2025 annual compensation as a member of the Board of Directors. The option vests in two equal installments on December 16, 2026 and December 16, 2027, meaning he earns the right to exercise half the option on each of those dates. The award was granted under the company’s 2021 Omnibus Equity Incentive Plan, as amended.